Sam Brusco, Associate Editor07.22.22
Tandem Diabetes Care has acquired infusion set developer Capillary Biomedical.
“Infusion sets provide people flexible options in insulin pump wearability, and we are dedicated to expanding our portfolio of sets to offer our customers even greater choice in personalizing their therapy management system,” John Sheridan, Tandem Diabetes Care president and CEO told the press. “Through this acquisition, and through our efforts with existing infusion set partners, we look forward to developing new and innovative infusion set solutions that are designed to extend wear time and enhance user experience, while reducing occlusions, body burden and waste.”
Capillary Biomedical’s extended wear infusion set technology is in development and not commercially available. Financial terms of the deal weren’t disclosed.
“Infusion sets provide people flexible options in insulin pump wearability, and we are dedicated to expanding our portfolio of sets to offer our customers even greater choice in personalizing their therapy management system,” John Sheridan, Tandem Diabetes Care president and CEO told the press. “Through this acquisition, and through our efforts with existing infusion set partners, we look forward to developing new and innovative infusion set solutions that are designed to extend wear time and enhance user experience, while reducing occlusions, body burden and waste.”
Capillary Biomedical’s extended wear infusion set technology is in development and not commercially available. Financial terms of the deal weren’t disclosed.